Showing 2041-2050 of 23138 results for "".
Parsing the Debate Over Embryonic Stem Cells
https://reachmd.com/programs/clinicians-roundtable/parsing-the-debate-over-embryonic-stem-cells/2972/While politicians debate whether there should be federal funding of embryonic stem cells, they might be over-looking a key point: the fact that all of the momentum in stem cell research is not in cells derived from human embryos at all. Randal Mills, the chief executive officer of Osiris TherapeuticATTRibute-CM Findings on Acoramidis and Cumulative CV Events
https://reachmd.com/programs/on-the-frontlines-of-attr-cm/attribute-cm-acoramidis-cv-events/49036/An exploratory analysis of the ATTRibute-CM trial revealed that acoramidis meaningfully reduces cumulative cardiovascular events as early as one month into treatment. Learn more about these findings and their implications for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) as Ryan QuiglDESTINY-Breast05: Additional Data From the Interim Analysis
https://reachmd.com/clinical-practice/oncology-hematology/destiny-breast05-additional-data-from-the-interim-analysis/49126/Check out the interim DESTINY-Breast05 analysis of T-DXd showing improved IDFS and manageable safety vs T-DM1 in high-risk HER2+ BC with residual disease.Targeting Senescent Cells
https://reachmd.com/series/c-suite-chats/targeting-senescent-cells/35960/Rubedo Life Science CEO Frederick Beddingfield III, MD, PhD, FAAD, FACMS, talks about the importance of addressing aging and senescence, and his company's investigational drug that targets pathological senescent cells and surrounding tissues that drive inflammaging and chronic degenerative diseasesTherapeutic Advances and Fighting for Authorizations
https://reachmd.com/programs/practical-dermatology/therapeutic-advances-and-fighting-for-authorizations/35890/Joel L. Cohen, MD, FAAD, and Leon Kircik, MD, FAAD, discuss the latest developments in psoriasis and atopic dermatitis, as well as the challenges involved with fighting for prior authorizations for the best therapies, at Music City SCALE 2025.Biologics for Inflammatory Bowel Disease: Maximizing Benefits, Avoiding Complications
https://reachmd.com/programs/crohns-colitis-foundation-perspectives/biologics-for-inflammatory-bowel-disease-maximizing-benefits-avoiding-complications/8476/Drs. Lea Ann Chen and Gary Lichtenstein discuss potential complications of biologics for patients with IBD.Mummy Powders, Chocolate Skulls, & Gladiator Blood: Historical Remedies That Didn't Make the Cut
https://reachmd.com/programs/rub-some-dirt-in-it/mummy-powders-chocolate-skulls-gladiator-blood-historical-remedies-didnt-make-cut/8262/Long before the infamous Hannibal Lector was eating liver with fava beans and a nice Chianti, the cure to some ailments was "just a corpse away."The Role of Allergists at the Grassroots of Medicine and Public Health
https://reachmd.com/programs/hot-topics-in-allergy/the-role-of-allergists-at-the-grassroots-of-medicine-public-health/4027/How are Medicare and health insurance companies affecting physicians and their patients' access to care? What can physicians do to influence policy at the local level? Dr. J. Allen Meadows, clinical instructor in the Montgomery Internal Medicine Residency Program at the University of Alabama at BirmDiagnosing and Managing Childhood Food Allergies
https://reachmd.com/programs/hot-topics-in-allergy/diagnosing-and-managing-childhood-food-allergies/3918/Because more children now live with food allergies than in decades past, at what point should a physician suspect that a patient might have a food allergy? What gastrointestinal symptoms are most common in children with food allergies? Dr. Scott Sicherer, associate professor of pediatrics at Mount SProstate Cancer Predictability: Can We Anticipate a Patient's Risk in 25 Years?
https://reachmd.com/programs/clinicians-roundtable/prostate-cancer-predictability-can-we-anticipate-patients-risk-25-years/2987/Can you predict a man’s risk of prostate cancer 25 years in the future? The data from this study indicates that PSA levels before age 50 is an indicator of future prostate cancer. Find out more about the prospective study conducted by a team of researchers from Memorial Sloane Kettering. Epidemiolog